Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Ovarian Neoplasms

  Free Subscription


1 Am J Surg Pathol
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Cancer Res
1 Gynecol Oncol
1 J Clin Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Surg Pathol

  1. ZAREI S, Wang Y, Jenkins SM, Voss JS, et al
    Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Am J Surg Pathol. 2019 Dec 23. doi: 10.1097/PAS.0000000000001419.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  2. JIANG J, Wang S, Wang Z, Cai J, et al
    HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Cancer Chemother Pharmacol. 2020 Aug 2. pii: 10.1007/s00280-020-04120.
    PubMed         Abstract available

    Cancer Res

  3. PALMER AC, Plana D, Gao H, Korn JM, et al
    A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-19-3850.
    PubMed         Abstract available

    Clin Cancer Res

  4. TAKENAKA M, Kobel M, Garsed DW, Fereday S, et al
    Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma is Not Associated with Pathological Misclassification of Tumor Histotype.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-18-3691.
    PubMed         Abstract available

    Gynecol Oncol

  5. LEE JM, Annunziata CM, Hays JL, Cao L, et al
    Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)33677.
    PubMed         Abstract available

    J Clin Oncol

  6. DISILVESTRO P, Colombo N, Scambia G, Kim BG, et al
    Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.